Ernexa Therapeutics (NASDAQ:ERNA) Trading Up 5.1% – Here’s Why

Ernexa Therapeutics Inc. (NASDAQ:ERNA) rose 5.1% during mid-day trading on Thursday . The company traded as high as $1.26 and last traded at $1.24. Approximately 64,433 shares changed hands during trading, a decline of 80% from the average daily volume of 317,420 shares. The stock had previously closed at $1.18.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Ernexa Therapeutics in a research note on Thursday. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Sell”.

Ernexa Therapeutics Trading Down 3.2%

The stock has a market cap of $9.42 million, a PE ratio of -0.40 and a beta of 6.25. The business has a 50-day moving average price of $1.28 and a 200 day moving average price of $1.43.

Ernexa Therapeutics (NASDAQ:ERNA) last announced its quarterly earnings data on Friday, November 7th. The company reported ($0.15) earnings per share (EPS) for the quarter.

Institutional Trading of Ernexa Therapeutics

An institutional investor recently bought a new position in Ernexa Therapeutics stock. Susquehanna International Group LLP acquired a new position in Ernexa Therapeutics Inc. (NASDAQ:ERNA) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 30,854 shares of the company’s stock, valued at approximately $34,000. Susquehanna International Group LLP owned 0.39% of Ernexa Therapeutics at the end of the most recent quarter. 70.55% of the stock is currently owned by institutional investors.

Ernexa Therapeutics Company Profile

Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc was founded in 2018 and is based in Cambridge, Massachusetts.